Por Renan Filho · 2026-10-19**Lead**
Philadelphia Eagles quarterback Jalen Hurts will reportedly miss the remainder of the 2026 NFL season after medical tests revealed the presence of blood clots in his lungs. The diagnosis, confirmed by multiple league sources including ESPN and NFL Network, was made during a routine check-up that escalated into an emergency imaging session. While the exact date of the discovery has not been publicly specified, the news broke late Monday evening, sending shockwaves through the sports world and raising questions about the technological protocols used to catch such conditions before they become fatal.
**Context**
Pulmonary embolism — a blockage in one of the pulmonary arteries in the lungs — is a known risk for athletes, particularly those who experience long periods of immobilization such as during flights, combined with the physical trauma common in contact sports. In Hurts’ case, the clots were detected after he complained of shortness of breath and chest discomfort following a Week 8 game against the Dallas Cowboys. Team physicians ordered a D-dimer blood test, which measures the presence of clot breakdown products, and the elevated results triggered an immediate CT pulmonary angiography.
CT pulmonary angiography is considered the gold standard for diagnosing pulmonary emboli. It involves injecting a contrast dye into the patient’s veins and using a high-speed spiral computed tomography scanner to produce detailed 3D images of the lung arteries. Modern CT systems used in NFL-affiliated medical centers can complete the scan in under 10 seconds while delivering radiation doses that have been significantly reduced through iterative reconstruction algorithms — a technology that has evolved rapidly over the past decade. The ability to quickly and accurately identify clots is critical; untreated pulmonary embolism has a mortality rate of nearly 30 percent, but with prompt diagnosis and anticoagulation therapy, that rate drops to below 5 percent.
Beyond the hospital setting, wearable health technology is playing an increasingly important role in the early detection of thromboembolic events. Many NFL players, including Hurts, use smart rings or smartwatches that continuously monitor heart rate, heart rate variability, blood oxygen saturation (SpO2), and even thoracic impedance. A sudden drop in SpO2 or an unexplained change in heart rate variability can be an early warning sign of a pulmonary embolism, prompting athletes to seek medical evaluation before symptoms become severe. The Eagles’ medical staff has access to a centralized health data platform that aggregates daily biometric readings from all players, allowing for longitudinal trend analysis. According to recent medical literature, such platforms have helped identify dozens of potential health issues across professional sports leagues, with one study from the NFL’s Engineering Committee noting a 15 percent improvement in early detection of respiratory complications since the widespread adoption of continuous monitoring in 2023.
**Analysis**
The Hurts case highlights a broader trend: the intersection of sports medicine, biotechnology, and data analytics is becoming a standard pillar of athlete care. The NFL has invested heavily in the NFL’s Digital Athlete initiative, which uses machine learning algorithms to analyze player health data and predict injury risk. While the league does not publicly disclose specific algorithmic models, it is known that these systems incorporate physiological, biomechanical, and even genetic risk factors. For conditions like venous thromboembolism (VTE), algorithms can flag players who have a combination of risk factors: recent surgery, prolonged travel, family history of clotting disorders, or a high body mass index. The Eagles, like many teams, also employ point-of-care ultrasound (POCUS) devices that can be used on the sideline to visualize deep vein thrombosis in the legs before clots travel to the lungs.
This event also raises questions about the ethical and privacy implications of such pervasive health monitoring. While players consent to data collection under the collective bargaining agreement, the line between proactive healthcare and surveillance is often debated. However, in a case where a life-threatening condition is detected early, the benefits are undeniable. Hurts is expected to be placed on blood thinners for several months and will undergo follow-up imaging to ensure the clots have resolved. His return to football will depend on the resolution of the clots and the absence of an underlying clotting disorder such as Factor V Leiden, which can be identified through genetic testing — another technological tool now commonly available.
From a competitive standpoint, the Eagles lose their franchise quarterback for the rest of the season, but the team emphasized that health comes first. Head coach Nick Sirianni stated, “Our medical team acted swiftly and used every diagnostic tool available. We are grateful that the technology exists to catch this early.” The incident is likely to accelerate the integration of routine D-dimer screening and advanced imaging into preseason physicals across the league, especially for players with a history of thromboembolic risk factors. It also serves as a reminder that even the most physically robust individuals are vulnerable to silent, technology-detectable threats.
**Sources**
- ESPN: Report on Jalen Hurts’ diagnosis and expected absence. - NFL Network: Confirmation of medical findings and team statement. - American College of Chest Physicians: Guidelines on pulmonary embolism diagnosis and treatment. - NFL Engineering Committee: Published data on wearable health monitoring in professional football. - Philadelphia Eagles official press release regarding Jalen Hurts’ medical status.